Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Myriad Genetics Inc.

Latest From Myriad Genetics Inc.

AML Contender Quizartinib Gains First Approval, In Japan

Japan grants first approval worldwide for Daiichi Sankyo's oral FLT3 inhibitor, marking progress for Japanese firm's global oncology ambitions.

Japan Approvals

Myriad Foresees Important Role For Genetic Testing In Pancreatic Cancer, Breast Cancer And Beyond

The results of the POLO trial, showing a benefit of Myriad’s BRACAnalysis CDx companion diagnostic for AstraZeneca’s Lynparza (olaparib) to treat pancreatic cancer offer more support for the new guidelines from the National Comprehensive Cancer Network recommending genetic testing for all pancreatic cancer patients. Myriad also stands to benefit from the growing support for genetic testing of breast cancer patients.

ASCO In Vitro Diagnostics

Patent Eligibility Bill May Carve Out Patenting Of Research

Witnesses at US Senate hearings debate bill's impact on drug pricing; discuss limiting it to medical diagnostics.

Legislation Intellectual Property

Battle Begins Over Legislation To Expand What Inventions May Be Patented

BIO, PhRMA, AAM, former PTO Commissioners to testify at two-day Senate hearing on draft bill to revise Section 101 of Patent Act; ACLU coalition says legislation will allow patenting of human genes.

Intellectual Property Legislation
See All

Company Information

  • Industry
  • Biotechnology
    • Pharmacogenetics-Pharmacogenomics
  • In Vitro Diagnostics
    • Molecular Diagnostics & Genetic Testing
  • Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Dermatology
  • Gynecological, Urological
  • Immune Disorders
  • Infectious & Viral Diseases
  • Neurology, Nervous System
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Myriad Genetics Inc.
  • Senior Management
  • Mark C Capone, Pres. & CEO
    R. Bryan Riggsbee, CFO
    Jerry H Lanchbury, PhD, CSO
    Mark H Pollack, MD, CMO
    Rishi Kacker, CTO
    Bryan M Dechairo, PhD, EVP, Clinical Dev.
  • Contact Info
  • Myriad Genetics Inc.
    Phone: (801) 584-3600
    320 Wakara Way
    Salt Lake City, UT 84108